Gastric Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology

Jaffer A. Ajani(The University of Texas MD Anderson Cancer Center), Lenora A. Pluchino(National Comprehensive Cancer Network)

Journal of the National Comprehensive Cancer Network

February 1, 2022

10.6004/jnccn.2022.0008

Cited by 1,680

Related Papers

Esophageal and Esophagogastric Junction Cancers, Version 2.2019, NCCN Clinical Practice Guidelines in Oncology

|Journal of the National Comprehensive Cancer Network|2019|1.1k

Zolbetuximab plus mFOLFOX6 in patients with CLDN18.2-positive, HER2-negative, untreated, locally advanced unresectable or metastatic gastric or gastro-oesophageal junction adenocarcinoma (SPOTLIGHT): a multicentre, randomised, double-blind, phase 3 trial

|The Lancet|2023|701

Zolbetuximab plus CAPOX in CLDN18.2-positive gastric or gastroesophageal junction adenocarcinoma: the randomized, phase 3 GLOW trial

|Nature Medicine|2023|541

Esophageal and Esophagogastric Junction Cancers, Version 2.2023, NCCN Clinical Practice Guidelines in Oncology

|Journal of the National Comprehensive Cancer Network|2023|494

Phase II Trial of Preoperative Chemoradiation in Patients With Localized Gastric Adenocarcinoma (RTOG 9904): Quality of Combined Modality Therapy and Pathologic Response

|Journal of Clinical Oncology|2006|385